Karyopharm Therapeutics Inc. (KPTI) vs Obsidian Therapeutics Inc. (OBX)

A side-by-side comparison of Karyopharm Therapeutics Inc. and Obsidian Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KPTI

Karyopharm Therapeutics Inc.

$15M

$0.67HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

OBX

Obsidian Therapeutics Inc.

$15M

$14.00HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

Total return — KPTI vs OBX

growth of $100 · dividends reinvested · last 1y

KPTI -90.5% (-90.5%/yr)OBX -20.9% (-20.9%/yr)OBX compounded faster over this window

Log scale — wide-divergence pair

KPTI OBX

Metrics side by side

Total return (annualized)

Metric	KPTI	OBX
Total return (1Y)	-89.38%	N/A
Total return CAGR (3Y)	-67.56%	N/A
Total return CAGR (5Y)	-62.18%	N/A
Total return CAGR (10Y)	-41.85%	N/A

OBX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full KPTI analysis Full OBX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.